Evaluating the MiLES Web-based Program to Help Employers Support Employees With Cancer in Returning to Work Successfully
Led by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Updated on 2024-11-04
140
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the MiLES intervention aimed at employers to help employees with cancer successfully return to work. This randomized controlled trial will compare the MiLES intervention to usual care, assessing its effectiveness, cost-effectiveness, and impact on quality of life for employees with cancer and their employers. The study includes 140 pairs of employees with cancer and their employers, focusing on improving return-to-work outcomes within a year.
The study involves two groups one where employers access the web-based MiLES intervention featuring interactive videos, conversation checklists, tips, and information to better support employees with cancer during sick leave and return to work and a control group receiving usual care without access to MiLES during the study. Employers in the control group will receive access to MiLES after a 12-month waiting period. The MiLES intervention encourages effective communication and support between employers and employees.
Participants will complete questionnaires at the start and at 3, 6, and 12 months to assess return to work, quality of life, work-related support, and satisfaction for both employees and employers. The study also evaluates employers confidence in providing support and satisfaction with the return-to-work process. Researchers will monitor outcomes and perform cost-effectiveness analyses from the employers perspective. The total follow-up period for each participant is 12 months.
CONDITIONS
Brief Title
Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention)
Research Team
J
Judith Mollet, MSc
M
Michiel Greidanus, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead Sponsor
Dutch Cancer Society
Collaborating Sponsor
Who Can Participate
Age: 18Years - 65Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Diagnosed with cancer less than 2 years ago
Aged between 18 and 65 years
Currently employed and sick-listed fully or partly for less than 2 years
Have an occupational physician or reintegration consultant involved
Able to read and understand Dutch
Have informed or intend to inform employer about the cancer diagnosis
Not applied for or planning to apply for an invalidity benefit under the WIA
Employer supports and guides the employee during sick leave and return to work
Employer can read and understand Dutch
Employer not familiar with the MiLES intervention
You will not qualify if you...
Employee and employer must participate together as a dyad; if one party cannot or will not participate, the other cannot participate either
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 months
Participants in the intervention group have their employers access the web-based MiLES intervention to support return to work. Participants in the control group receive usual care without access to the MiLES intervention during the study period.
Questionnaires at baseline and at 3, 6, and 12 months
Follow-up
Duration - 12 months
Participants complete follow-up assessments to evaluate return to work, quality of life, work-related support, and satisfaction with the return to work process over 12 months.
Questionnaires at 3, 6, and 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Tracking COVID-19 Antibody Levels Over Time in Adults With Cancer Receiving Chemotherapy, Targeted Therapy, or Immunotherapy
Study of 18F-FAPI-04 PETCT and PETMR Scans for Detecting and Monitoring Various Cancers
18F-grazy-02 PETCT Imaging to Monitor Immunotherapy Responses in Adults with Lung Cancer or Melanoma
PETCT Imaging Using 68Ga-ICAM-1pep to Monitor Tumor Response to Radiotherapy in Adults with Cancer
Study of 68Ga-NYM096 PETCT Imaging to Measure Tracer Uptake in Different Types of Cancer Including Primary and Metastatic Tumors
PET Imaging Using 68GaGa-Sa-DABI-4 to Detect Stimulator of Interferon Gene Expression in Adults with Cancer
Behavioral Intervention to Help Young LatinoHispanic Men with Cancer Manage Emotions and Life Goals
Prospective Clinical and Biological Database of Cancer Patients Starting Anticancer Immunotherapy
Tracking Immune-Related Side Effects Over Time
Phase I Trial Evaluating Safety and Dose of PA5 Intravenous Treatment for Adults With Advanced Solid Tumors
Evaluation of COM503 Alone or with Zimberelimab for Safety and Dosage in Adults with Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effectiveness, cost-effectiveness, and return on investment of the web-based MiLES intervention targeted at employers, to enhance successful return to work of employees with cancer: design of a randomized controlled trial.
Judith M Mollet, Michiel A Greidanus, Cécile R L Boot...